Compare Dr. Reddy's Laboratories Ltd Common Stock (RDY) vs Synopsys, Inc. (SNPS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Dr. Reddy's Laboratories Ltd Common Stock vs Synopsys, Inc. — how do they compare? Dr. Reddy's Laboratories Ltd Common Stock trades at $12.75 (market cap $10.61B), while Synopsys, Inc. trades at $473 (market cap $91.97B). The key difference: Synopsys, Inc. is far larger — about 8.7× Dr. Reddy's Laboratories Ltd Common Stock's market cap, and Dr. Reddy's Laboratories Ltd Common Stock pays a 0.65% dividend while Synopsys, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Dr. Reddy's Laboratories Ltd Common Stock for 0 Days and Synopsys, Inc. for 72 Days on average.
| RDY | SNPS | |
|---|---|---|
Market Cap | $10.61B | $91.97B |
Volume | 3,738,869 | 3,203,530 |
Sector | Health | Technology |
52-Week High | $15.38 | $534.56 |
52-Week Low | $11.38 | $367.70 |
Typical Hold Time | 0 Days | 72 Days |
Enterprise Value | $10.51B | $99.21B |
Dividend Yield | 0.65% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Synopsys (SNPS) trades at $494.51, down 1.59% on the day, but maintains a strong bullish technical trend with recent price action supported by positive investor sentiment. The company reported three consecutive quarterly earnings beats, with Q2 2026 EPS of $3.91 exceeding the $3.67 estimate. Recent partnerships with OpenAI and Amazon Web Services, including a $1 billion deal, have driven optimism and a 13% stock surge, highlighting its strategic positioning in AI-driven chip design.
The outlook for SNPS is positive, supported by robust analyst consensus, with 28 of 30 analysts rating it a Buy and a consensus price target of $575.93 implying significant upside. Key risks include high valuation multiples, such as a P/E of 86.3, and integration challenges from the Ansys acquisition. Revenue growth is projected to accelerate, with 2026 guidance surpassing expectations, though margin compression remains a watch point.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Dr. Reddy's Laboratories Ltd Common Stock
Dr. Reddy's Laboratories Ltd. develops and manufactures generic medicines, active pharmaceutical ingredients (APIs), biosimilars, and over-the-counter (OTC) products, headquartered in Hyderabad, India, with therapeutic focus areas spanning gastrointestinal, cardiovascular, oncology, and dermatology.
Read more on RDY →About Synopsys, Inc.
Synopsys is a provider of electronic design automation software, intellectual property, and software integrity products. EDA software automates the chip design process, enhancing design accuracy, productivity, and complexity in a full-flow end-to-end solution. The firm's growing SI business allows customers to continuously manage and test the code base for security and quality. Synopsys' comprehensive portfolio is benefiting from a mutual convergence of semiconductor companies moving up-stack toward systems-like companies, and systems companies moving down-stack toward in-house chip design. The resulting expansion in EDA customers alongside secular digitalization of various end markets benefits EDA vendors like Synopsys.
Read more on SNPS →
